Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 October 2017)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 111 US patents relevant to Australia's Life Sciences sector that were granted in 2016, for an issuance rate of 2.1 per week:

US Patent 9,527,908, Modified variable domain molecules and methods for producing them, Garvan Institute of Medical Research, 27 December 2016
US Patent 9,526,734, Formulation of meloxicam, iCeutica, 27 December 2016
US Patent 9,522,214, Viscous haemostatic compositions and method of treatment, Eupharma, 20 December 2016
US Patent 9,518,127, Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses, CSL Ltd, 13 December 2016
US Patent 9,518,109, Prevention, treatment and diagnosis of P. gingivalis infection, Oral Health Australia Pty Ltd, 13 December 2016
US Patent 9,518,089, Metallothionein-derived peptide fragments, University of Tasmania, 13 December 2016
US Patent 9,511,080, Okadaella gastrococcus and cancer Takayuki Okada, 6 December 2016
US Patent 9,511,031, Controlled release doxycycline, Mayne Pharma, 6 December 2016
US Patent 9,511,017, Method and composition for use in preparation of a patient for surgery, Novapharm Research (Australia) Pty Ltd, 6 December 2016
US Patent 9,498,525, Treatment or prophylaxis of asthma, Hunter Immunology, 22 November 2016
US Patent 9,492,552, Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative, Jurox Pty Ltd, 15 November 2016
US Patent 9,492,547, Polymorphic form of inulin and uses thereof, Vaxine Pty Ltd, 15 November 2016
US Patent 9,486,497, Treatment of immunocompromised conditions, University of Queensland, 8 November 2016
US Patent 9,480,717, Composition of whey growth factor extract for reducing muscle inflammation, Murray Goulburn Co-Operative, 1 November 2016
US Patent 9,474,789, Methods and compositions for promoting organ growth and development, Kintan Pty Ltd, 25 October 2016
US Patent 9,474,270, Methods and compositions for controlling pests, Bioprospect and University of Western Sydney, 4 October 2016
US Patent 9,458,093, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems (ASX: VBS), 4 October 2016
US Patent 9,457,107, Cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 4 October 2016
US Patent 9,457,062, Chaperonin 10-induced immunomodulation, Invion (ASX: IVX), 4 October 2016
US Patent 9,452,148, Insulin sensitisers and methods of treatment, Verva Pharmaceuticals, 27 September 2016
US Patent 9,452,037, Delivery of oral care products, OBJ Ltd (ASX: OBJ), 27 September 2016
US Patent 9,447,080, Viral polymerase inhibitors, Biota, 20 September 2016
US Patent 9,446,057, Controlled release doxycycline, Mayne Pharma (ASX: MYX), 20 September 2016
US Patent 9,441,239, Methods and means for obtaining modified phenotypes, Commonwealth Scientific and Industrial Research Organisation, 13 September 2016
US Patent 9,440,926, Antiviral compounds and methods, Biotron (ASX: BIT), 13 September 2016
US Patent 9,439,946, Reconstituted high density lipoprotein formulation and production method thereof, CSL Ltd (ASX: CSL), 13 September 2016
US Patent 9,433,805, Method for dermal regeneration by administering an ether cross-linked glucomannan/hyaluronic acid composition, Ultraceuticals, 6 September 2016
US Patent 9,428,587, Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof, Biosceptre International, 30 August 2016
US Patent 9,427,443, Anaesthetic composition, Jurox Pty Ltd, 30 August 2016
US Patent 9,422,522, Method of producing adipocytes from fibroblast cells, Regenertech Pty Ltd (Dr Vishal Bhasin), 23 August 2016
US Patent 9,421,205, FAK inhibitors, Cancer Therapeutics CRC , 23 August 2016
US Patent 9,415,063, Treatment of neurological disorders, Velacor Therapeutics, 16 August 2016
US Patent 9,408,919, Biodegradable polymer-bioactive moiety conjugates, PolyActiva Pty Ltd, 9 August 2016
US Patent 9,408,824, Compositions and products containing S-equol, and methods for their making, Sanitarium with Cincinnati Children's Hospital (United States), 9 August 2016
US Patent 9,402,902, Composition and method for the treatment and prevention of enteric bacterial infections, Immuron (ASX: IMC), 2 August 2016
US Patent 9,402,896, Method of inducing tolerance to an allergen, Murdoch Childrens Research Institute, 2 August 2016
US Patent 9,394,353, Method for improving the stability of purified factor VIII after reconstitution, CSL Ltd (ASX: CSL), 19 July 2016
US Patent 9,393,287, Methods and compositions for promoting organ development, Kintan Pty Ltd, 19 July 2016
US Patent 9,393,274, Control of sucking lice, Dudley Pinnock and David Cooper, 19 July 2016
US Patent 9,387,218, Composition for the treatment of inflammatory and immune disorders, Eaglepharma Pty Ltd (Paul Turner), 12 July 2016
US Patent 9,387,213, Small molecules inhibiting oncoprotein Myc, Panacela Labs (part owned by Children's Cancer Institute Australia), 12 July 2016
US Patent 9,381,262, Methods for radiolabeling synthetic polymers, Australian National University, 5 July 2016
US Patent 9,381,240, Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors, Queensland Department of Agriculture and Fisheries with Meat & Livestock Australia, 5 July 2016
US Patent 9,376,682, Method of treating pulmonary disease by administering an antibody to G-CSF, CSL Ltd (ASX: CSL), 28 June 2016
US Patent 9,371,530, Modulation of growth hormone receptor expression and insulin-like growth factor expression, Antisense Therapeutics (ASX: ANP), 21 June 2016
US Patent 9,365,829, Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof, University of Technology, Sydney, 14 June 2016
US Patent 9,365,650, Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa, Baker IDI Heart and Diabetes Institute, 14 June 2016
US Patent 9,364,570, Functionalisation of cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 14 June 2016
US Patent 9,364,534, Treatment of neurological conditions, CSL Ltd (ASX: CSL), 14 June 2016
US Patent 9,364,016, Extracts derived from sugar cane and a process for their manufacture, The Product Makers (Australia) Pty Ltd, 14 June 2016
US Patent 9,359,422, Single chain relaxin polypeptides, University of Queensland with Florey Institute of Neuroscience and Mental Health, 7 June 2016
US Patent 9,359,377, Substituted imidazo[1,2-a]imidazo[4',5':4,5]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections, Biota, 7 June 2016
US Patent 9,358,247, Methods and compositions for promoting activity of anti-cancer therapies, ORIL, 7 June 2016
US Patent 9,357,783, Methods and compositions for controlling ectoparasites, Hatchtech Pty Ltd, 7 June 2016
US Patent 9,353,152, Induction of the mitochondrial permeability transition, University of New South Wales, 31 May 2016
US Patent 9,352,038, Treatment of neurological conditions, CSL Ltd (ASX: CSL), 31 May 2016
US Patent 9,352,034, Methods of treating pain using an antibody specific for GM-CSF, University of Melbourne, 31 May 2016
US Patent 9,351,977, Methods of reducing mammographic breast density and/or breast cancer risk, Chavah Pty Ltd , 31 May 2016
US Patent 9,346,842, Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics (ASX: BNO), 24 May 2016
US Patent 9,345,911, Methods of inducing melanogenesis in a subject, Clinuvel Pharmaceuticals (ASX: CUV), 24 May 2016
US Patent 9,345,667, Particles having hydrophobic material therein, Australian Nuclear Science & Technology Organisation, 24 May 2016
US Patent 9,340,622, Synthetic immunogen useful for generating long lasting immunity and protection against pathogens, University of Melbourne with the Council of Scientific and Industrial Research (India), 17 May 2016
US Patent 9,340,583, VIP fragments and methods of use, Vectus Biosystems (ASX: VBS), 17 May 2016
US Patent 9,340,517, Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor, Mimetica Pty Ltd, 17 May 2016
US Patent 9,328,164, Anti-nerve growth factor antibodies and methods of preparing and using the same, NVIP, 3 May 2016
US Patent 9,328,155, Peptides for inducing antibodies to a non-functional P2X7 receptor, BioSceptre, 3 May 2016
US Patent 9,326,539, Compositions comprising dietary fat complexers and methods for their use, Soho Flordis International, 3 May 2016
US Patent 9,320,755, Therapeutic and diagnostic molecules, Centenary Institute with University of Sydney and the Wenkart Foundation, 26 April 2016
US Patent 9,315,581, Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 19 April 2016
US Patent 9,314,527, Transdermal delivery patch, Phosphagenics (ASX: POH), 19 April 2016
US Patent 9,314,450, Combination therapy, Dimerix (ASX: DXB), 19 April 2016
US Patent 9,308,193, Kinase inhibitors for the treatment of cancer, PharmAust (ASX: PAA), 12 April 2016
US Patent 9,303,026, Antiviral agents, Biota, 5 April 2016
US Patent 9,302,993, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 5 April 2016
US Patent 9,299,476, Polymeric material, University of New South Wales, 29 March 2016
US Patent 9,295,654, Layered nanoparticles, Australian Nuclear Science & Technology Organisation, 29 March 2016
US Patent 9,295,652, Controlled release doxycycline, Mayne Pharma (ASX: MYX), 29 March 2016
US Patent 9,295,628, Stabilized calcium phosphate complexes, University of Melbourne, 29 March 2016
US Patent 9,290,577, Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 22 March 2016
US Patent 9,289,586, Spreading implement, Acrux (ASX: ACR), 22 March 2016
US Patent 9,289,410, Tiglien-3-one derivatives, QBiotics, 22 March 2016
US Patent 9,289,381, Stabilization and storage of biological pharmaceutical compositions, Monash University with University of North Carolina at Charlotte (US) and Charlotte-Mecklenburg Hospital Authority (US) , 22 March 2016
US Patent 9,283,365, Patch production, University of Queensland, 15 March 2016
US Patent 9,283,291, Methods for radiolabeling macromolecules, Australian National University, 15 March 2016
US Patent 9,283,212, Pharmaceutical preparation and delivery system, Palmaya Pty Ltd (Dr George O'Neil), 15 March 2016
US Patent 9,278,134, Dual functioning ionic liquids and salts thereof, Monash University with University of Alabama (US) and Queen's University Belfast (UK), 8 March 2016
US Patent 9,273,125, Human monoclonal antibody having fat-reducing effect, Patrys (ASX: PAB), 1 March 2016
US Patent 9,272,046, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma (ASX: MYX), 1 March 2016
US Patent 9,271,982, Animal feed supplement comprising ractopamine and caffeine, Rivalea, 1 March 2016
US Patent 9,271,503, Control of insect pests, Innovate Ag, 1 March 2016
US Patent 9,268,908, Computer systems for treating diseases, Biotempus, 23 February 2016
US Patent 9,266,864, VEGFR3 inhibitors, Cancer Therapeutics CRC, 23 February 2016
US Patent 9,265,817, PAT-LM1 epitopes and methods for using same, Patrys (ASX: PAB), 23 February 2016
US Patent 9,265,726, Foamable suspension gel, Stiefel Research Australia, 23 February 2016
US Patent 9,265,249, Dispersants in high-electrolyte solutions, Huntsman Corporation Australia, 23 February 2016
US Patent 9,260,691, Methods relating to an attenuated mycoplasma, Bioproperties Pty Ltd, 16 February 2016
US Patent 9,260,526, Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Opthea (ASX: OPT), 16 February 2016
US Patent 9,254,322, Compositions comprising E-selectin antagonists and uses therefor, University of Queensland, 9 February 2016
US Patent 9,254,288, Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof, Queensland University of Technology with the Translational Genomics Research Institute (US), 9 February 2016
US Patent 9,247,766, Angiogenin-enriched milk fractions, Murray Goulburn Co-Operative with Agriculture Victoria Services, 2 February 2016
US Patent 9,243,066, Use of M-CSF antibodies in the treatment of osteoarthritis or pain, University of Melbourne with MorphoSys (Germany), 26 January 2016
US Patent 9,243,061, Osteoarthritis treatment, University of Melbourne, 26 January 2016
US Patent 9,242,007, Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells, EnGeneIC, 26 January 2016
US Patent 9,241,952, Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin, OzStar Therapeutics, 26 January 2016
US Patent 9,241,883, Ionic complexes, University of Melbourne, 26 January 2016
US Patent 9,239,904, Computer systems for treating diseases, Biotempus, 19 January 2016
US Patent 9,238,644, VEGFR3 inhibitors, Cancer Therapeutics CRC, 19 January 2016
US Patent 9,238,054, Treatment of kidney fibrosis with VIP fragments, Vectus Biosystems (ASX: VBS), 19 January 2016
US Patent 9,238,001, Delivery system for remote treatment of an animal, Smartvet Pty Ltd, 19 January 2016
US Patent 9,234,019, Modified Cpn10 and PRR signalling, Invion (ASX: IVX), 12 January 2016
US Patent 9,226,939, Histone inhibition, Australian National University, 5 January 2016

New Zealand applications

Here are the 16 US patents relevant to New Zealand's Life Sciences sector that were granted in 2016, for an issuance rate of 0.3 applications per week:

US Patent 9,522,159, Treatment and prevention of P. aeruginosainfections using coformycin analogs, Viclink (Victoria University of Wellington, 20 December 2016
US Patent 9,469,675, Anti-inflammatory proteins and methods of preparation and use thereof, ManukaMed, 18 October 2016
US Patent 9,452,155, Injectable antibiotic formulations and their methods of use, Bayer New Zealand, 27 September 2016
US Patent 9,415,061, Compositions and methods for treatment of neoplastic disease, Innate Immunotherapeutics (ASX: IIL), 16 August 2016
US Patent 9,375,413, Methods of reducing milk somatic cell count, AgResearch Ltd, 28 June 2016
US Patent 9,359,392, Dendrimer scaffolds for pharmaceutical use, Viclink (Victoria University of Wellington), 28 June 2016
US Patent 9,353,349, Synthetic membrane anchors, Kode Biotech, 31 May 2016
US Patent 9,339,479, Dosage forms and related therapies, PhilERA (Professor Garth Cooper), 17 May 2016
US Patent 9,320,781, Dietary supplement for managing gut health, Vital Foods, 26 April 2016
US Patent 9,315,587, Oligosaccharide compounds, Viclink (Victoria University of Wellington) with University of Liverpool (UK), 19 April 2016
US Patent 9,314,505, Combination treatments and compositions for wound healing comprising viral VEGF, Otago Innovation (University of Otago), 19 April 2016
US Patent 9,314,478, Method of making an anhydrous, fat soluble, chewable drug delivery formulation, Argenta, 19 April 2016
US Patent 9,296,789, Vaccines and vaccine components for inhibition of microbial cells, Pastoral Greenhouse Gas Research, 29 March 2016
US Patent 9,290,501, Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase, Viclink (Victoria University of Wellington) with Albert Einstein College of Medicine (US), 22 March 2016
US Patent 9,255,109, Fungicidal compounds and methods of their use, Auckland UniServices (University of Auckland), 9 March 2016
US Patent 9,226,968, Carbohydrate-lipid constructs and their use in preventing or treating viral infection, Kode Biotech, 5 January 2016